Pharma Strategic Deal: Astellas Pharma to acquire Audentes Therapeutics for about $3 billion
Posted on05 Dec 2019
TagsAstellas, Astellas Pharma, biopharma business development, Pharma Business Development, pharma strategic deal
Comments0
Astellas Pharma Inc. anannounced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00... Read More
Astellas to acquire Universal Cells for up to $102.5M
Astellas Pharma has acquired Seattle, WA-based Universal Cells, Inc. and its Universal Donor Cell technology enabling the creation of cell therapy products... Read More
Case Study: Astellas Pharma’s acquisition of a Belgian biotech company – Ogeda
Astellas Pharma is acquiring Ogeda, getting hold of its promising Phase II candidate to treat menopause without hormonal therapy. After acquiring Ganymed... Read More
Grünenthal to Acquire Commercialization Rights of Qutenza® in Europe from Astellas Pharma Europe
Grünenthal will hold exclusive rights for Qutenza® in all 28 European Union member states, Switzerland, Iceland, Norway and Lichtenstein, and other East... Read More
Excelra, Astellas Pharma enter drug repurposing collaboration
Excelra, Asia’s leading knowledge solutions company, has entered into a strategic drug repurposing collaboration with Tokyo-based pharmaceutical company, Astellas Pharma Inc. The... Read More